Gen-Probe (US) licenses patented tests to Becton Dickinson (US):
This article was originally published in Clinica
Executive Summary
Gen-Probe (US) has granted Becton Dickinson (US) a non-exclusive worldwide right to its patented methods for detecting vaginosis and vaginitis. In exchange for the rights to patent nos 4,851,330 and 5,288,611, Becton will make an upfront payment of an undisclosed sum and pay a royalty on sales of the licensed products. Becton says it will also defend Gen-Probe's patents against further infringement. The patents are "in a disease category that Gen-Probe currently has no plans to enter", says president and CEO Henry Nordhoff.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.